5 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 5 of 5 clinical reviews.
Resmetirom (Rezdiffra) lowers FibroScan liver stiffness and CAP scores in MASH patients. Review of MAESTRO-NASH data, monitoring timelines, and clinical interpretation of VCTE changes on therapy.
Resmetirom (Rezdiffra) lowers Free T4 through selective THR-β agonism. Learn the expected magnitude, time course, monitoring schedule, and when changes require clinical action.
Resmetirom (Rezdiffra) significantly lowers LDL cholesterol, triglycerides, apolipoprotein B, and lipoprotein(a) through selective thyroid hormone receptor beta activation in the liver. Review the MAESTRO-NASH lipid data, monitoring timelines, and clinical implications.
Resmetirom (Rezdiffra) is a selective thyroid hormone receptor beta agonist approved for MASH. Learn how it affects Free T3 levels, what is established versus unverified about the magnitude of change, and how to think through monitoring.
Resmetirom (Rezdiffra) selectively activates thyroid hormone receptor beta in the liver, which can suppress TSH in some patients. This article covers the mechanism, what the FDA label says, and a practical monitoring framework, while flagging which specific figures still need primary-source verification.